Science Explorer Back to mapMap

Most cited papers from Rocky Mountain Cancer Centers

What are the most cited papers from Rocky Mountain Cancer Centers?

The most cited paper from Rocky Mountain Cancer Centers is "Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC" (Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al., 2018), with 3,816 citations. Next come "Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma" (3,488) and "Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer" (1,671).

Showing 50 of 60 papers. Every paper with more than 133 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine Open access 4 Jun 2018 3,816
2 Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Brian I. Rini et al. · New England Journal of Medicine Open access 16 Feb 2019 3,488
3 Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer Aditya Bardia et al. · New England Journal of Medicine Open access 21 Apr 2021 1,671
4 Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA M.C. Liu et al. · Annals of Oncology Open access159 authors 30 Mar 2020 1,567
5 Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial Elizabeth M. Swisher et al. · The Lancet Oncology Open access 28 Nov 2016 1,218
6 Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study Josep M. Tabernero, Takayuki Yoshino, Allen Lee Cohn et al. · The Lancet Oncology 12 Apr 2015 967
7 Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial Martin Reck et al. · The Lancet Respiratory Medicine 26 Mar 2019 954
8 Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma Toni K. Choueiri et al. · New England Journal of Medicine Open access 18 Aug 2021 792
9 Tumor Characteristics and Clinical Outcome of Elderly Women With Breast Cancer Sami Diab · JNCI Journal of the National Cancer Institute 5 Apr 2000 680
10 Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer Nancy U. Lin et al. · Clinical Cancer Research Open access 15 Feb 2009 666
11 Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Blood Open access 4 Mar 2014 646
12 Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial Robert M. Jotte, Federico Cappuzzo, Ihor O. Vynnychenko et al. · Journal of Thoracic Oncology Open access 14 Apr 2020 618
13 Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor William D. Tap et al. · New England Journal of Medicine 29 Jul 2015 593
14 TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors Scott T. Tagawa, Arjun Vasant Balar, Daniel Peter Petrylak et al. · Journal of Clinical Oncology Open access 30 Apr 2021 553
15 IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC Mark A. Socinski, Makoto Nishio, Robert M. Jotte et al. · Journal of Thoracic Oncology Open access 24 Jul 2021 546
16 Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer Vicky Makker, Matthew Hiram Taylor, Carol A Aghajanian et al. · Journal of Clinical Oncology Open access 13 Mar 2020 531
17 Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer Georgiana Kehr Ellis, Henry G. Bone, Rowan T. Chlebowski et al. · Journal of Clinical Oncology 25 Aug 2008 484
18 Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial Vicky Makker, Drew Warren Rasco, Nicholas J. Vogelzang et al. · The Lancet Oncology Open access 26 Mar 2019 482
19 Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma Shaji Kunnathu Kumar, Ian W. Flinn, Paul Gerard Guy Richardson et al. · Blood 16 Mar 2012 453
20 An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer A. Ashworth, Suresh Senan, David A. Palma et al. · Clinical Lung Cancer 15 May 2014 439
21 Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial Jennifer Keating Litton, Sara A. Hurvitz, Lida A. Mina et al. · Annals of Oncology Open access 20 Aug 2020 412
22 Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 Mark J. Roschewski, Michail S. Lionakis, Jeff Porter Sharman et al. · Science Immunology Open access 5 Jun 2020 380
23 Palliative Care for Patients With Cancer: ASCO Guideline Update Justin J. Sanders, Sarah Temin, Arunangshu Ghoshal et al. · Journal of Clinical Oncology Open access 15 May 2024 352
24 Evaluation of cell-free DNA approaches for multi-cancer early detection Arash Jamshidi et al. · Cancer Cell Open access 17 Nov 2022 335
25 IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain Naoyuki Nogami et al. · Journal of Thoracic Oncology Open access 7 Oct 2021 313
26 Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180 Steven Peter Treon, Leukothea Ioakimidis, Jacob Drobnyk Soumerai et al. · Journal of Clinical Oncology Open access 9 Jun 2009 294
27 Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2 Amit M. Oza et al. · Gynecologic Oncology Open access 4 Sep 2017 282
28 Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes Roger M. Lyons, Thomas M. Cosgriff, Sanjiv Modi et al. · Journal of Clinical Oncology 3 Mar 2009 276
29 High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study Richard A. Nash et al. · Blood Open access 24 Apr 2007 265
30 Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial Jeffrey Howard Lipton et al. · The Lancet Oncology 12 Apr 2016 264
31 Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation Mohamed Lotfy Sorror, Barry E. Storer, Brenda M. Sandmaier et al. · Cancer Open access 29 Feb 2008 264
32 Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial Saad Zafar Usmani et al. · The Lancet Haematology Open access117 authors 18 Jul 2019 249
33 Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153 David Michael Waterhouse et al. · Journal of Clinical Oncology Open access 10 Sep 2020 247
34 Safety and Efficacy of 68 Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors Stephen A. Deppen, Eric Liu, Jeffrey D. Blume et al. · Journal of Nuclear Medicine Open access 14 Jan 2016 237
35 Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370) David Robert Spigel, Craig H. Reynolds, David Michael Waterhouse et al. · Journal of Thoracic Oncology Open access 6 Mar 2018 230
36 Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes Hillel P. Cohen, Andrew Blauvelt, Robert M. Rifkin et al. · Drugs ReviewOpen access Mar 2018 222
37 Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) Elizabeth M. Swisher et al. · Nature Communications Open access 3 May 2021 209
38 Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Joëlle Roche, Ferenc L. Boldog, Misi Robinson et al. · PubMed 21 Mar 1996 195
39 Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · JAMA Oncology Open access 16 Feb 2023 193
40 Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153) David Robert Spigel et al. · Journal of Thoracic Oncology Open access 20 May 2019 190
41 Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study Chung‐Han Lee et al. · The Lancet Oncology Open access 15 Jun 2021 189
42 Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248 Steven Peter Treon, Zachary R. Hunter, Jeffrey Matous et al. · Clinical Cancer Research Jun 2007 188
43 Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia HA Drabkin, C Parsy, Kevin L. Ferguson et al. · Leukemia Feb 2002 187
44 Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy Robert M. Jotte, Paul Conkling, Craig H. Reynolds et al. · Journal of Clinical Oncology 7 Dec 2010 178
45 Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia Irene M. Ghobrial, Fangxin Hong, Swaminathan Padmanabhan et al. · Journal of Clinical Oncology Open access 9 Feb 2010 166
46 Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma Nathan Hale Fowler et al. · Journal of Clinical Oncology Open access 8 Mar 2021 163
47 Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS- mutated non-small cell lung cancer with STK11 , KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial Howard West, Mark L. McCleland, Federico Cappuzzo et al. · Journal for ImmunoTherapy of Cancer Open access Feb 2022 155
48 Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial Daniel Peter Petrylak et al. · The Lancet Oncology 2 Mar 2015 151
49 Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia Irene M. Ghobrial, Wanling Xie, Swaminathan Padmanabhan et al. · American Journal of Hematology 10 Jun 2010 150
50 Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia Steven Peter Treon, Andrew Robert Branagan, Leukothea Ioakimidis et al. · Blood Open access 18 Nov 2008 148

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.